RVPH vs. FULC, FHTX, URGN, ACB, LRMR, LFCR, GOSS, INBX, LXEO, and CRDF
Should you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Fulcrum Therapeutics (FULC), Foghorn Therapeutics (FHTX), UroGen Pharma (URGN), Aurora Cannabis (ACB), Larimar Therapeutics (LRMR), Lifecore Biomedical (LFCR), Gossamer Bio (GOSS), Inhibrx (INBX), Lexeo Therapeutics (LXEO), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry.
Reviva Pharmaceuticals vs.
Fulcrum Therapeutics (NASDAQ:FULC) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk.
Reviva Pharmaceuticals' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.
In the previous week, Reviva Pharmaceuticals had 12 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 14 mentions for Reviva Pharmaceuticals and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.70 beat Reviva Pharmaceuticals' score of 0.75 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.
Fulcrum Therapeutics has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500.
Reviva Pharmaceuticals has lower revenue, but higher earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Fulcrum Therapeutics received 73 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 89.29% of users gave Reviva Pharmaceuticals an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote.
89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 4.1% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Fulcrum Therapeutics currently has a consensus target price of $9.33, suggesting a potential upside of 129.89%. Reviva Pharmaceuticals has a consensus target price of $11.25, suggesting a potential upside of 612.03%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Fulcrum Therapeutics.
Summary
Reviva Pharmaceuticals beats Fulcrum Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Reviva Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reviva Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RVPH) was last updated on 1/15/2025 by MarketBeat.com Staff
Free RVPH Stock Alerts